Workflow
抗癌药格列卫
icon
Search documents
关税全部由美国人买单!10月1日生效,特朗普对进口药征100%关税
Sou Hu Cai Jing· 2025-09-29 05:30
Core Viewpoint - The recent tariff reforms in the U.S. are significantly increasing costs for consumers and businesses, leading to a rapid decline in purchasing power for ordinary families [3][15]. Pharmaceutical Industry - The pharmaceutical sector is facing severe disruptions, with companies like Novo Nordisk having to re-label diabetes medication due to a 100% tariff, resulting in an additional $700 per box [6]. - Sumitomo Pharma anticipates a direct loss of $435 million in profits from the U.S. market due to tariffs on its cancer drug [6]. - The lengthy FDA approval process (28 months) complicates the transition to alternative production, exacerbating supply issues for U.S. patients [6][9]. Supply Chain Impact - Indian pharmaceutical companies are pressured to reduce raw material prices by 5%, while facing an 18% increase in steel prices due to tariffs [8]. - U.S. pharmaceutical companies are also struggling, with Pfizer experiencing a 22% increase in the cost of imported vaccine components [8]. Trucking Industry - The trucking sector is heavily impacted, with a 25% tariff causing each truck to cost an additional $87,500, leading to production delays and potential shutdowns [9]. - Domestic companies like PACCAR are facing increased costs due to a 40% rise in steel prices and doubled costs for German robotics, resulting in an estimated $12,000 increase in truck production costs [9]. Furniture Market - The furniture industry is seeing a significant drop in demand, with a 45% price increase from Vietnamese suppliers driving away 60% of American customers [13]. - Ashley Furniture is also affected, facing a 22% increase in domestic lumber prices and a 35% tariff on Vietnamese hardware, raising the cost of cabinets by $380 [13]. Global Economic Impact - The IMF reports that the tariff situation will create an additional $120 billion in trade costs, with 70% of this burden falling on American consumers [15]. - Despite the projected $350 billion investment in new pharmaceutical plants, the R&D processes remain largely overseas, indicating a fragmented production model that may lead to inefficiencies for global consumers [15].